6.74

2.74% -0.19

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Financials Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is traded at $6.74, with a volume of 1.45M. It is down -2.74% in the last 24 hours and down -11.66% over the past month. Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Previous Close:

$6.93

Open:

$6.86

24h Volume:

1.45M

Relative Volume:

1.50

Market Cap:

$953.02M

Revenue:

$62.04M

Net Income/Loss:

$-533.34M

P/E Ratio:

-1.5011

EPS:

-4.49

Net Cash Flow:

$-473.07M

1W Performance:

-24.94%

1M Performance:

-11.66%

6M Performance:

-30.44%

1Y Performance:

-31.22%

1-Day Range:

$6.62

$7.025

1-Week Range:

$6.62

$9.095

52-Week Range:

$6.62

$13.09

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

415-906-4324

Address

1800 OWENS STREET, SAN FRANCISCO, CA

Employee

587

Twitter

@Vir_Biotech

Next Earnings Date

2024-10-31

Latest SEC Filings

VIR's Discussions on Twitter

Compare VIR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIR	6.74	953.02M	62.04M	-533.34M	-473.07M	-4.49
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

Nov 20, 2024

Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Nov 20, 2024

Empowered Funds LLC Decreases Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat

Nov 20, 2024

Nov 19, 2024

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace

Nov 19, 2024

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace

Nov 19, 2024

Nov 18, 2024

VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan

Nov 18, 2024

Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan

Nov 18, 2024

EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com

Nov 18, 2024

EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada

Nov 18, 2024

Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com

Nov 18, 2024

Vir Biotechnology Secures Key EU Orphan Drug Status for Hepatitis Delta Treatment | VIR Stock News - StockTitan

Nov 18, 2024

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com

Nov 18, 2024

Nov 16, 2024

Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat

Nov 16, 2024

Nov 15, 2024

(VIR) Proactive Strategies - Stock Traders Daily

Nov 15, 2024

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance

Nov 15, 2024

Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com

Nov 15, 2024